Mallinckrodt stock tumbles after new Citron Research report targets $40,000-a-vial drug | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 5 June, 2017 by The TZ Newswire Staff

Mallinckrodt stock tumbles after new Citron Research report targets $40,000-a-vial drug

The short-seller claimed a recent development could send Mallinckrodt shares to zero and make the company bankrupt.
read more

See also
- Next Article The Ratings Game: Skechers’ wholesale business has potential, but Foot Locker may be wrong-footed by Amazon
- Previous Article White House’s Sanders grilled about Trump’s ‘travel ban,’ London tweets
Editorial Calender

June 2017

M T W T F S S

1 2 3 4

5 6 7 8 9 10 11

12 13 14 15 16 17 18

19 20 21 22 23 24 25

26 27 28 29 30

« May Jul »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar